ABBVIE INC. - ABBV STOCK NEWS

AbbVie presented data on investigational epcoritamab at the 64th ASH Annual Meeting on December 11, 2022. Epcoritamab is being evaluated for relapsed/refractory follicular lymphoma, previously untreated follicular lymphoma, relapsed/refractory diffuse large B-cell lymphoma, and Richter's syndrome. In the EPCORE™ NHL-2 study, 95% of patients with R/R FL achieved an overall response rate, while 94% in the previously untreated FL arm also showed positive results. Epcoritamab's safety profile indicated manageable low-grade cytokine release syndrome (CRS) and common treatment-emergent adverse events.

AbbVie recently presented data from Cohort 3 of the Phase 2 REFINE study at the ASH Annual Meeting, focusing on its investigational drug navitoclax combined with ruxolitinib for JAK inhibitor-naïve myelofibrosis patients. This combination therapy showed promise in reducing bone marrow fibrosis and variant allele frequency associated with myelofibrosis. Notably, spleen volume reduction was observed in various high-risk patient subgroups, and BMF grade improvement was seen in 81% of participants. The study indicates potential disease-modifying effects, although safety assessments showed common adverse events.

AbbVie presented new data at the 64th ASH Annual Meeting on IMBRUVICA (ibrutinib) for chronic lymphocytic leukemia (CLL), focusing on the CAPTIVATE and GLOW studies. Findings showed that patients with confirmed undetectable minimal residual disease experienced high progression-free survival rates, with 95% for those continuing IMBRUVICA vs. 88% for placebo. Additionally, real-world studies indicated that IMBRUVICA treatment yielded longer time to next treatment compared to other therapies. The continued investigation of IMBRUVICA reinforces its position in CLL treatment.

AbbVie has announced a collaboration with HotSpot Therapeutics to develop the first small molecule IRF5 inhibitor for treating autoimmune diseases. The deal includes an upfront payment of $40 million and potential total payments of $295 million in milestones and royalties. This collaboration aims to enhance AbbVie's immunology pipeline, targeting conditions like systemic lupus erythematosus. HotSpot’s Smart Allostery™ platform has enabled the discovery of this novel inhibitor, marking significant progress in the treatment of poorly managed autoimmune disorders.

AbbVie (NYSE: ABBV) will present 15 abstracts showcasing its migraine treatment portfolio at the 16th European Headache Federation Congress (EHC 2022) in Vienna from December 7-10, 2022. The highlights include late-breaking data from the CaMEO-I study on neck pain and the PROGRESS Phase 3 trial results for atogepant, aimed at preventing chronic migraine in Europe. AbbVie emphasizes its commitment to addressing the challenges faced by those living with migraines, asserting its leadership in migraine research and treatment solutions.

AbbVie (NYSE: ABBV) will present at the 5th Annual Evercore ISI Virtual HealthCONx Conference on November 29, 2022, at 9:55 a.m. Central time. Key executives including Rob Michael, Jeffrey R. Stewart, Scott Reents, and Tom Hudson will participate in the session. Investors can access a live audio webcast through AbbVie's Investor Relations website, with an archived version available later that day. AbbVie focuses on innovative medicines across various therapeutic areas, including immunology and oncology.

AbbVie announced the European Commission's approval of SKYRIZI (risankizumab) as the first IL-23 inhibitor for treating adults with moderately to severely active Crohn's disease. This approval, significant for patients with inadequate responses to other therapies, is supported by the Phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. Results indicated that patients on SKYRIZI showed better clinical remission and endoscopic response rates at both 12 and 52 weeks compared to placebo. The treatment is integral to AbbVie's growing IBD portfolio, aiming to alleviate symptoms and improve patient outcomes.

AbbVie (NYSE: ABBV) will present nearly 65 abstracts, including 15 oral presentations, at the upcoming American Society of Hematology (ASH) annual congress from December 10-13, 2022. The presentations will cover 8 types of blood cancers, highlighting investigational and approved therapies such as epcoritamab and navitoclax. Data aims to showcase advancements in treating chronic lymphocytic leukemia and multiple myeloma. The company emphasizes a commitment to improving patient outcomes in blood cancers, although many therapies are still under evaluation and not yet approved.